GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lirum Therapeutics Inc (NAS:LRTX) » Definitions » Liabilities-to-Assets

Lirum Therapeutics (Lirum Therapeutics) Liabilities-to-Assets : 0.48 (As of Dec. 2023)


View and export this data going back to 2024. Start your Free Trial

What is Lirum Therapeutics Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Lirum Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $2.18 Mil. Lirum Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $4.57 Mil. Therefore, Lirum Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.48.


Lirum Therapeutics Liabilities-to-Assets Historical Data

The historical data trend for Lirum Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lirum Therapeutics Liabilities-to-Assets Chart

Lirum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Liabilities-to-Assets
- 5.68 0.48

Lirum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Sep23 Dec23
Liabilities-to-Assets - - 5.68 0.42 0.48

Competitive Comparison of Lirum Therapeutics's Liabilities-to-Assets

For the Biotechnology subindustry, Lirum Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lirum Therapeutics's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lirum Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Lirum Therapeutics's Liabilities-to-Assets falls into.



Lirum Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Lirum Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=2.18/4.569
=0.48

Lirum Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as

Liabilities-to-Assets (Q: Dec. 2023 )=Total Liabilities/Total Assets
=2.18/4.569
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lirum Therapeutics  (NAS:LRTX) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Lirum Therapeutics Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Lirum Therapeutics's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lirum Therapeutics (Lirum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
590 Madison Avenue, 21st Floor, New York, NY, USA, 10022
Lirum Therapeutics Inc is clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases through the acquisition, development, and commercialization of novel drug candidates with compelling mechanisms of action, regulatory pathways, and commercial opportunities. Its product candidate, LX-101, formerly 765IGF-MTX, is a novel, clinical-stage, "next generation," precision-engineered targeted therapy directed to the IGF-1R.

Lirum Therapeutics (Lirum Therapeutics) Headlines

No Headlines